Observational studyBMJ open2018
Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study.
Observational study in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimizing the Care Pathways of Patients Treated for Operable Breast Cancer
Professional Life After Breast Cancer: Feasibility of a Coaching Program for an Adapted Return to Work
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic factors for return to work in breast cancer survivors.The Cochrane database of systematic reviews · 2025Pooled it
- Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.Advances in therapy · 2024Pooled it
- Recent Status and Methodological Quality of Return-to-Work Rates of Cancer Patients Reported in Japan: A Systematic Review.International journal of environmental research and public health · 2019Pooled it
- Understanding nonresponse and strategies to improve response rates in a randomized controlled trial among breast cancer survivors: the FASTRACS-INSIGHT mixed-methods study.Journal of cancer survivorship : research and practice · 2026Article
- The Societal Burden of Breast Cancer in Working-Age Women in Croatia: A Multicentre Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Measures of Work-life Balance and Interventions of Reasonable Accommodations for the Return to Work of Cancer Survivors: A Scoping Review.Safety and health at work · 2024Article
- Return to work, work productivity loss and activity impairment in Chinese breast cancer survivors 12-month post-surgery: a longitudinal study.Frontiers in public health · 2024Observational
- Impact of breast cancer care pathways and related symptoms on the return-to-work process: results from a population-based French cohort study (CONSTANCES).Breast cancer research : BCR · 2023Article
- Facilitating Factors and Barriers in the Return to Work of Working Women Survivors of Breast Cancer: A Qualitative Study.Cancers · 2023Article
- Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis.Frontiers in oncology · 2023Article
- Return to Work and Mortality in Breast Cancer Survivors: A 11-Year Longitudinal Study.International journal of environmental research and public health · 2022Article
- Variation over time of the factors influencing return to work and work capacities after a diagnosis of breast cancer: a study on the behalf of the Seintinelles research network.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Views of breast cancer survivors on work participation guidance by general practitioners: a qualitative study.BMC primary care · 2022Article
- Article
- Return to Work and Work Productivity During the First Year After Cancer Treatment.Frontiers in psychology · 2022Article
- Prosigna test in breast cancer: real-life experience.Breast cancer research and treatment · 2021Article
- Impact of Breast Cancer Diagnosis and Treatment on Work-Related Life and Financial Factors.Breast care (Basel, Switzerland) · 2021Article
- Predictors of resignation and sick leave after cancer diagnosis among Japanese breast cancer survivors: a cross-sectional study.BMC public health · 2021Article
- Article
- Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReturn to work (RTW) after breast cancer (BC) is still a new field of research. The factors determining shorter sick leave duration of patients with BC have not been clearly identified. The aim of this study was to describe work during BC treatment and to identify factors associated with sick leave duration. MATERIALS AND
methodsAn observational, prospective, multicentre study was conducted among women with operable BC. A logbook was given to all working patients to record sociodemographic and work-related data over a 1-year period.
resultsWork-related data after BC were available for 178 patients (60%). The median age at diagnosis was 50 years (27-77), 87.9% of patients had an invasive form of BC and 25.3% a lymph node involvement. 25.9% had a radical surgery and 24.2% had an axillary dissection. Radiotherapy was performed in 90.9% of patients and chemotherapy in 48.1%. Sick leave was prescribed for 165 patients (92.7%) for a median of 155 days. On univariate analysis, invasive BC (p=0.025), lymph node involvement (p=0.005), radical surgery (p=0.025), axillary dissection (p=0.004), chemotherapy (p<0.001), personal income <€1900/month (p=0.03) and not having received the patient information booklet on RTW (p=0.047) were found to be associated with a longer duration of sick leave. On multivariate analysis, chemotherapy was found to be associated with longer sick leave (OR: 3.5; 95% CI 1.6 to 7.9; p=0.002). The cost of sick leave to French National Health Insurance was fourfold higher in the case of chemotherapy (p<0.001).
conclusionAdvanced disease and chemotherapy are major factors that influence sick leave duration during the management of BC. TRIAL REGISTRATION NUMBER: NCT02813317.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.